GlassScriptPhysician profile
Anupama Kale
NPI 1467765784
$68,780.57
in general payments reported to CMS, 2019-2025
85 companies · $3,754 in 2025
The $3,754 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,923 · 2020: $2,710 · 2021: $15K · 2022: $11K · 2023: $25K · 2024: $9,709 · 2025: $3,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,130 · Travel and Lodging: $3,468 · Honoraria: $3,029 · Education: $2,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,200.00 |
| Food and Beverage | $10,169.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,130.00 |
| Travel and Lodging | $3,468.26 |
| Honoraria | $3,029.00 |
| Education | $2,587.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $21,594.00 | 2019-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $11,583.42 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Amneal Pharmaceuticals LLC | $7,786.10 | 2019-2025 | Ongentys, Crexont, Ongentys 50mg Capsules 30 |
| Adamas Pharmaceuticals, INC. | $6,691.78 | 2020-2021 | |
| Kyowa Kirin, INC. | $3,724.77 | 2019-2024 | Nourianz |
| Abbvie INC. | $1,477.47 | 2021-2025 | |
| Ucb, INC. | $1,196.32 | 2019-2025 | Nayzilam, Rystiggo, Briviact |
| Sunovion Pharmaceuticals INC. | $1,004.43 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $1,003.60 | 2019-2025 | Austedo Xr, Austedo, Truxima |
| Novartis Pharmaceuticals Corporation | $877.16 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $859.87 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $699.91 | 2019-2025 | Ultomiris, Soliris |
| Avanir Pharmaceuticals, INC. | $577.65 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $552.19 | 2019-2022 | |
| Abbott Laboratories | $508.41 | 2019-2023 | Infinity, Octrode |
Show all 83 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$524,062.14 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anupama Kale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.